Clinical Trial: A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension

U.S., June 17 -- ClinicalTrials.gov registry received information related to the study (NCT07650084) titled 'A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension' on June 10.

Brief Summary: This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Study Start Date: Nov. 21, 2025

Study Type: INTERVENTIONAL

Condition: Refractory Chronic Cough

Intervention: DRUG: BLU-5937

Oral administration of BLU-5937 Tablets.

DRUG: Placebo

Oral administration of matching placebo for BLU-5937 Tablets.

Recruitment Status: RECRUITING

Sponsor: GlaxoSmithKline

Published by HT Digital Content Services ...